W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

Aktualności

22 February, 2023
Opinion of the Transparency Council – amendments to the drug programme B.47
read more
22 February, 2023
Opinion of the Transparency Council – stiripentol
read more
22 February, 2023
Opinion of the Transparency Council – amendments to the drug programme B.90
read more
22 February, 2023
Position of the Transparency Council – Apexxnar
read more
22 February, 2023
Position of the Transparency Councii – Lorviqua (lorlatinib)
read more
22 February, 2023
Opinion of the Transparency Council – venlafaxine
read more
22 February, 2023
Opinion of the Transparency Council – metformin
read more
22 February, 2023
Opinion of the Transparency Council – chloroquine
read more
22 February, 2023
Position of the Transparency Council – Keytruda (pembrolizumab) eTNBC
read more
22 February, 2023
Position of the Transparency Council – Keytruda (pembrolizumab) mTNBC
read more
22 February, 2023
Position of the Transparency Council – Beovu (brolucizumab)
read more
22 February, 2023
Position of the Transparency Councii – Ofev (nintedanib)
read more
22 February, 2023
Position of the Transparency Council – Brukinsa (zanubrutinib)
read more
22 February, 2023
Opinion of the Transparency Council – health policy pof the City of Opole in the field of early detection of hearing and vision impairment in children
read more
22 February, 2023
Opinion of the Transparency Council – M-TYPER
read more
22 February, 2023
Position of the Transparency Council – Verzenios (abemaciclib)
read more
22 February, 2023
Position of the Transparency Council – Libtayo (cemiplimab)
read more
22 February, 2023
Position of the Transparency Council – Reducto spezial (potassium dihydrogen phosphate, sodium monohydrogen phosphate)
read more
22 February, 2023
Position of the Transparency Council – Fostex Nexthaler (beclometasone dipropionate) anhydrous + formoterol fumarate dihydrate
read more
21 February, 2023
The Transparency Council meeting 9/2023 on 27 February 2023
read more
16 February, 2023
Meeting of the Transparency Council 8/2023 on 20 February 2023 – UPDATE
read more
14 February, 2023
The Meeting of the Tariffs Council No. 5/2023 of 23.02.2023
read more
14 February, 2023
The Meeting of the Transparency Council No. 8/2023 of 20.02.2023
read more
13 February, 2023
Communication on the meeting of the Tariff Council on 9 February 2023
read more

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑